Li Pang Source Confirmed

Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.

High Impact

Researcher

National Center for Toxicological Research

faculty

22 h-index 86 pubs 2,500 cited

Is this your profile? Verify and claim your profile

Biography and Research Information

OverviewAI-generated summary

Li Pang's research focuses on investigating the mechanisms of toxicity and developing methods for assessing drug safety, particularly in the areas of cardiovascular and hepatic health. Recent work includes studies on the use of human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) for evaluating drug-induced cardiotoxicity, including proof-of-concept studies with doxorubicin. Pang has also investigated the effects of preparation methods on delayed repolarization evaluations using iPSC-CMs and explored the impairment of liver mitochondrial functions by pexidartinib in primary human hepatocytes.

Further research extends to the development of novel drug delivery systems, such as cationic polymeric micellar structures with endosomal escape capabilities designed for enhanced intramuscular transfection of mRNA-lipid nanoparticles. Pang's work also encompasses the validation and use of New Approach Methodologies (NAMs) for toxicity screening and drug development. With a career marked by 86 publications and over 2,500 citations, Pang is recognized as a highly cited researcher. Key collaborators include William B. Mattes, Katy S Papineau, Lijun Ren, and Prathyusha Bagam, all from the National Center for Toxicological Research, with whom Pang has co-authored multiple publications.

Metrics

  • h-index: 22
  • Publications: 86
  • Citations: 2,500

Selected Publications

  • Validating and Using Cardiac NAMs for Toxicity Screening and Drug Development (2025) DOI
  • Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations (2025) DOI
  • Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin (2024) DOI
  • New Alternative Methods in Drug Safety Assessment (2023) DOI
  • Use of Human iPSC-CMs in Nonclinical Regulatory Studies for Cardiac Safety Assessment (2022) DOI
  • Effects of Serum and Compound Preparation Methods on Delayed Repolarization Evaluation With Human iPSC-CMs (2022) DOI

Collaborators

Researchers in the database who share publications

Similar Researchers

Based on overlapping research topics